These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 37907724)

  • 1. Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies.
    Ruella M; Korell F; Porazzi P; Maus MV
    Nat Rev Drug Discov; 2023 Dec; 22(12):976-995. PubMed ID: 37907724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies.
    Xiao X; Wang Y; Zou Z; Yang Y; Wang X; Xin X; Tu S; Li Y
    Front Immunol; 2022; 13():954235. PubMed ID: 36091028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
    Zhang P; Zhang Y; Ji N
    Front Immunol; 2022; 13():927132. PubMed ID: 35874698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy.
    Lindo L; Wilkinson LH; Hay KA
    Front Immunol; 2020; 11():618387. PubMed ID: 33643299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukapheresis for CAR-T cell production and therapy.
    Pessach I; Nagler A
    Transfus Apher Sci; 2023 Dec; 62(6):103828. PubMed ID: 37838564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of bone marrow microenvironment on CAR-T efficacy in haematologic malignancies.
    Gao D; Hong F; He A
    Scand J Immunol; 2023 Aug; 98(2):e13273. PubMed ID: 39007933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the Etiology of Pancytopenias in the CAR T-Cell Therapy Setting: What We Know and What We Don't?
    Yassine F; Murthy H; Ghabashi E; Kharfan-Dabaja MA; Iqbal M
    Hematol Oncol Stem Cell Ther; 2022 Nov; 15(3):122-130. PubMed ID: 36633964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice.
    Gajra A; Zalenski A; Sannareddy A; Jeune-Smith Y; Kapinos K; Kansagra A
    Pharmaceut Med; 2022 Jun; 36(3):163-171. PubMed ID: 35672571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities.
    Ho M; Zanwar S; Paludo J
    Eur J Haematol; 2024 Feb; 112(2):197-210. PubMed ID: 37545132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis.
    Grigor EJM; Fergusson DA; Haggar F; Kekre N; Atkins H; Shorr R; Holt RA; Hutton B; Ramsay T; Seftel M; Jonker D; Daugaard M; Thavorn K; Presseau J; Lalu MM
    BMJ Open; 2017 Dec; 7(12):e019321. PubMed ID: 29288188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy.
    Dreyzin A; Rankin AW; Luciani K; Gavrilova T; Shah NN
    Expert Rev Clin Immunol; 2024 Jul; 20(7):745-763. PubMed ID: 38739466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haematology laboratory parameters to assess efficacy of CD19-, CD22-, CD33-, and CD123-directed chimeric antigen receptor T-cell therapy in haematological malignancies.
    Drumheller B; Gebre K; Lockhart B; Margolskee E; Obstfeld A; Paessler M; Pillai V
    Int J Lab Hematol; 2022 Aug; 44(4):750-758. PubMed ID: 35419923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Research Progress on the Influence of Blood Tumor Microen-vironment on the Efficacy and the Adverse Reactions of CAR-T Cell Immunotherapy--Review].
    Liao CF; Lai HR; Li J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Aug; 32(4):1290-1294. PubMed ID: 39192433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies.
    Kim SJ; Yoon SE; Kim WS
    Ann Lab Med; 2024 May; 44(3):210-221. PubMed ID: 38205527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes.
    Roselli E; Faramand R; Davila ML
    J Clin Invest; 2021 Jan; 131(2):. PubMed ID: 33463538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in research on factors affecting chimeric antigen receptor T-cell efficacy.
    Zhou D; Zhu X; Xiao Y
    Cancer Med; 2024 Jun; 13(11):e7375. PubMed ID: 38864474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined or Sequential Treatment with Immune Checkpoint Inhibitors and Car-T Cell Therapies for the Management of Haematological Malignancies: A Systematic Review.
    Pérez-Moreno MA; Ciudad-Gutiérrez P; Jaramillo-Ruiz D; Reguera-Ortega JL; Abdel-Kader Martín L; Flores-Moreno S
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Application of CAR-T Cells in Haematological Malignancies.
    Skorka K; Ostapinska K; Malesa A; Giannopoulos K
    Arch Immunol Ther Exp (Warsz); 2020 Nov; 68(6):34. PubMed ID: 33156409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
    Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
    Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric Antigen Receptors for the Tumour Microenvironment.
    Habib R; Nagrial A; Micklethwaite K; Gowrishankar K
    Adv Exp Med Biol; 2020; 1263():117-143. PubMed ID: 32588326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.